Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.
| Autor: | Sarver M; Department of Surgery, Duke University, Durham, NC, USA., Brown MC; Department of Neurosurgery, Duke University, Durham, NC, USA., Rhodin KE; Department of Surgery, Duke University, Durham, NC, USA., Salama AKS; Department of Medicine, Duke University, Durham, NC, USA., Beasley GM; Department of Surgery, Duke University, Durham, NC, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 May 31; Vol. 18 (3), pp. 1943987. Date of Electronic Publication: 2021 Jul 13. |
| DOI: | 10.1080/21645515.2021.1943987 |
| Abstrakt: | This review describes the current body of literature and ongoing clinical trials examining neoadjuvant immune checkpoint inhibitors (ICI) for patients with resectable stage III and IV melanoma. Based on prior success in treating metastatic melanoma and as adjuvant therapy, ICIs are being explored in the neoadjuvant setting. There have been initial trials and there are many ongoing trials examining neoadjuvant ICI. Herein, we will review the clinical feasibility and efficacy of various neoadjuvant ICI regimens, explore pathologic and cellular responses, and present factors associated with predictive tumor response. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|